Cytek Biosciences, Inc. (CTKB) Stock Overview
Explore Cytek Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Cytek Biosciences, Inc. (CTKB)
Key Financials
Key Financials
Market Cap
740M
P/E Ratio
-9.28
EPS (TTM)
$-0.19
ROE
-0.24%
CTKB Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Cytek Biosciences, Inc. (NASDAQ: CTKB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Cytek Biosciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CTKB on the NASDAQ shows an RSI of 76.96, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $5.23 for the NASDAQ listing.
Key metrics behind Cytek Biosciences, Inc.'s NASDAQ-traded stock include a P/E ratio of -9.28 and a market capitalization of 740M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CTKB on the NASDAQ.